Aclaris Therapeutics
ACRS
3.38
-0.02
-0.71%
Aclaris Therapeutics
US · ACRS
#3750 by market cap
Listed 2015
3.38
-0.02
-0.71%
Live - 5344 symbols - heartbeat 278s ago
· 2026-10-08 10:00
Pre-market
3.44
+1.11%
After-hours
3.46
+1.76%
Overnight
3.39
-0.29%
- Market cap
- 496.94M
- P/E (TTM)i
- -5.82
- P/Bi
- 3.99
- EPSi
- -0.53
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on ACRS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 1.6 percentage points.
Institutional ownership
- Held by institutions
- 84.13% -1.63pp
- Institutions
- 173
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund31.22%
Mutual Fund26.64%
Hedge Fund24.78%
Individual/Insider2.21%
Public Company0.78%
Private Company0.40%
Insurance Company0.17%
Government Pension Fund0.10%
Other13.68%
Top holders as of 2026-06-30
RA Capital Management, L.P.
8.64% · 12.72M sh
BML Capital Management, LLC
8.14% · 11.98M sh
BlackRock
6.82% · 10.04M sh
Deep Track Capital, LP
6.35% · 9.35M sh
Frazier Life Sciences Management, LP
5.93% · 8.73M sh
Vanguard Capital Management, LLC
4.57% · 6.73M sh
Vivo Capital, LLC
4.55% · 6.69M sh
Rock Springs Capital Management LP
2.94% · 4.33M sh
Adage Capital Management, L.P.
2.77% · 4.07M sh
Decheng Capital LLC
2.75% · 4.04M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 40 buys · 10 sells
| Name | Role | Stake |
|---|---|---|
| Neal Walker | Chairperson | 1.05% |
| Anand Mehra | Independent Director | 0.49% |
| Joseph Monahan | Chief Scientific Officer | 0.18% |
| James Loerop | Chief Business Officer | 0.13% |
| Kevin Balthaser | Chief Financial Officer | 0.13% |
| Christopher Molineaux | Lead Independent Director | 0.05% |
| Hugh M. Davis | President | 0.03% |
| William Humphries | Independent Director | 0.03% |
| Douglas Manion | Chief Executive Officer | 0.03% |
| Maxine Gowen | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-31 | Roland Kolbeck | Chief Scientific Officer | Derivative Exercise and Sale | -12,385 | $5.20 |
| 2026-07-31 | Roland Kolbeck | Chief Scientific Officer | Derivative Exercise and Retained | +23,990 | -- |
| 2026-06-04 | Vincent Milano | Independent Director | Derivative Exercise and Retained | +11,580 | -- |
| 2026-06-04 | Andrew Schiff | Independent Director | Derivative Exercise and Retained | +11,580 | -- |
| 2026-06-04 | Maxine Gowen | Independent Director | Derivative Exercise and Retained | +11,580 | -- |
| 2026-06-04 | William Humphries | Independent Director | Derivative Exercise and Retained | +11,580 | -- |
| 2026-06-04 | Anand Mehra | Independent Director | Derivative Exercise and Retained | +11,580 | -- |
| 2026-06-04 | Christopher Molineaux | Lead Independent Director | Derivative Exercise and Retained | +11,580 | -- |
| 2026-06-03 | Vincent Milano | Independent Director | Other Derivative Acquisition | +10,987 | -- |
| 2026-06-03 | Vincent Milano | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 |
| 2026-06-03 | Andrew Schiff | Independent Director | Other Derivative Acquisition | +10,987 | -- |
| 2026-06-03 | Andrew Schiff | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 |
| 2026-06-03 | Maxine Gowen | Independent Director | Other Derivative Acquisition | +10,987 | -- |
| 2026-06-03 | Maxine Gowen | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 |
| 2026-06-03 | William Humphries | Independent Director | Other Derivative Acquisition | +10,987 | -- |
| 2026-06-03 | William Humphries | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 |
| 2026-06-03 | Anand Mehra | Independent Director | Other Derivative Acquisition | +10,987 | -- |
| 2026-06-03 | Anand Mehra | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 |
| 2026-06-03 | Christopher Molineaux | Lead Independent Director | Other Derivative Acquisition | +10,987 | -- |
| 2026-06-03 | Christopher Molineaux | Lead Independent Director | Other Derivative Acquisition | +42,350 | $4.71 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:00:33 · For reference only, not investment advice and not tailored to your situation.